Metabolic & Cardiometabolic
glucose variability predicts cardiovascular risk in non-diabetics
In plain terms: Does blood-sugar "variability" on a CGM predict heart disease in healthy people?
Variability tracks surrogate risk markers, but direct hard-outcome CV evidence in non-diabetics is limited, so the "predicts CVD" claim is not established.
📅 Last reviewed: 2026-07-14 ⓘ
Evidence ladder
How far up the ladder this claim has climbed. A high consensus on a low rung means "consistent so far," not "proven in people."
Top evidence so far: Population patterns (Observational)
How the studies fall
What the evidence shows
Variability tracks surrogate markers: in 6,462 non-diabetic adults under 65, higher visit-to-visit glucose variability predicted risk, and lower continuous-monitoring time-in-range tracked worsening arterial stiffness. Hard cardiovascular outcome data in non-diabetics is essentially absent, and a twelve-week exercise trial moved vascular markers without moving variability.
The evidence (12)
| Source | Grade | Stance | Quality | Finding |
|---|---|---|---|---|
| Sato F, Mita T, Katakami N, Okada Y, Yoshii H, Osonoi T, Nishida K, Shiraiwa T, Ishii R, Gosho M, Shimomura I, Watada H 2026 · J Clin Endocrinol Metab | observational | mixed | moderate | Lower CGM-derived time-in-range was longitudinally associated with worsening arterial stiffness, but in type 2 diabetes rather than non-diabetic subjects. |
| Jang JY, Moon S, Cho S, Cho KH, Oh CM 2019 · Sci Rep | observational | supports | moderate | In 6,462 nondiabetic adults under 65y, higher visit-to-visit HbA1c/fasting/post-load glucose variability was associated with increased macro- and microvascular events. |
| Sparks JR, Sarzynski MA, Davis JM, Grandjean PW, Wang X 2021 · Int J Environ Res Public Health | observational | tested-null | low | In overweight/obese non-diabetics, 12-wk exercise changed vascular/oxidative markers but CGM glycemic variability did NOT change — decoupling variability from vascular outcomes. |
| Liao X, Li Y, Tang S, Xiao Y, Yu X, Huang R, Zhong T 2026 · Eur J Med Res | meta-analysis | mixed | low | CGM in non-diabetic populations can modify glycemic and behavioral metrics, but the review found no hard-outcome data tying CGM-derived variability to cardiovascular events in healthy people. |
| Qian T, Guo D, Zhang M, Liu Y, Jin J 2026 · Diabet Med | mechanism | mixed | low | Perspective, not evidence: 'this perspective articulates a unified three-pillar closed-loop framework'; 'We synthesize evidence from prospective cohorts, mechanistic studies, randomized controlled trials and real-world data'. No new data on GV and CV outcomes in non-diabetics. Review — zero weight. |
| Wu C, Li A, Zhu Q, Guo J, Li Y, Gu X, Sun A, Wei M, Gong Y 2025 · Front Endocrinol | meta-analysis | mixed | moderate | HbA1c variability was linked to incident CVD and mortality, but the association is established in type 2 diabetes, not in non-diabetic individuals. |
| Wilczek F, van der Stouwe JG, Petrasch G, Niederseer D 2025 · Sensors (Basel) | observational | mixed | low | SR of CGM in non-diabetics: data scarce, effect on cardiovascular outcomes unclear; only potential/surrogate benefit, no hard-endpoint prediction demonstrated. |
| An HM, Yeo SH, Chung HJ, Cho HS, Bae SJ, Kim JY, Kang DR, Lee MY, Lee JY 2021 · Eur Rev Med Pharmacol Sci | observational | supports | moderate | Visit-to-visit fasting blood sugar variability was associated with higher cardiovascular disease and mortality risk in a general population that was largely non-diabetic. |
| Liu Y, Xu H, Li J, Yang Y, Zhang J, Liu X, Li J, Yu Y, Qin G 2022 · Diabetes Obes Metab | observational | mixed | moderate | Visit-to-visit glucose variability predicts all-cause mortality — but population is type 2 diabetes, not non-diabetics; not CGM-measured. |
| Ahmed N, Elzein Ali MF, Hamed Mohamed MN, Mohammed Saad Aldeen RSA, Ibrahim Omer RI, Adam Omer TM, ElTahir Hamza RA, Musa Rabih MR 2025 · Cureus | observational | mixed | moderate | Systematic review (7 studies) in non-diabetics: higher glycemic variability linked to surrogate markers (e.g. BP variability) but direct evidence on hard cardiovascular endpoints remains limited. |
| Costantino S, Paneni F, Battista R, Castello L, Capretti G, Chiandotto S, Tanese L, Russo G, Pitocco D, Lanza GA, Volpe M, Lüscher TF, Cosentino F 2017 · Diabetes | mechanism | supports | moderate | Glycemic variability drives chromatin remodeling, oxidative stress and endothelial dysfunction — but in type 2 diabetics at target HbA1c, not healthy people; mechanism only. |
| Darouei B, Amani-Beni R, Kakavand N, Seifnezhad A, Mazaheri-Tehrani S, Shekarian A, Eshraghi R, Bahrami A, Amini-Salehi E, Hashemi SM, Movahed MR, Taub PR, Umpierrez G 2025 · Diabetol Metab Syndr | meta-analysis | mixed | low | Glycemic variability (MAGE, SD) predicted adverse cardiovascular events, but the pooled evidence came from patients with pre-existing cardiovascular disease rather than healthy people. |
Disagree, or know a study we missed?
We grade by evidence, not opinions. The way to weigh in is to point us to a study we haven't cited (check the evidence table above first), or to flag a problem with one we have. Every submission is reviewed; if it holds up, the grade updates and shows in Science Changes Its Mind.
Opens a short form. You'll sign in with Google so submissions are tied to a real account — we don't display your identity, and we only accept a link we can verify (PubMed, DOI, ClinicalTrials.gov).
Educational only, not medical advice. Grades and scores reflect published evidence weighted by study design and quality; see the methodology.